NCT07064174Recruiting
Sickle Cell Kidney Biorepository
Sickle Cell Kidney (SCeK) Biorepository
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 2 Jul 2025
- Start date
- 22 Aug 2024
- Primary completion date
- 31 Dec 2049
- Lead sponsor
- University of Texas Southwestern Medical Center
- NCT number
- NCT07064174
What you commit to
- Study type: Observational
- Planned participants: 800
- From 22 Aug 2024 to the primary completion date, 31 Dec 2049
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active malignancy on induction or consolidation treatment. Maintenance chemotherapy in remission will be considered,
Age
- Age 66 years or older,
Other
- Estimated glomerular filtration rate less than 15 mL/min or on dialysis,
- Active pregnancy (may be enrolled 4 weeks or more after delivery),
- Active sickle cell pain episode requiring hospitalization or emergency room visit or pain infusion clinic visit (may be enrolled 2 weeks or more after resolution of severe pain),
- Prisoners.
Who the study is looking for
- Age over 18 years,
- Estimated glomerular filtration rate greater than or equal to 15 mL/min,
- Presence of any hemoglobinopathy (will need to be confirmed by hemoglobin electrophoresis or genetic testing),
- Controls (absence of hemoglobinopathy) will be subject to review and only selected if demographics are identical to a currently enrolled participant with a hemoglobinopathy.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| Parkland Memorial Hospital Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.